Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
TSHA
vs
S&P 500
TSHA
S&P 500
Over the past 12 months, TSHA has outperformed S&P 500, delivering a return of +12% compared to S&P 500's +11% growth.
Stocks Performance
TSHA vs S&P 500
Performance Gap
TSHA vs S&P 500
Create a free account · No card needed
Performance By Year
TSHA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Taysha Gene Therapies Inc
Glance View
Taysha Gene Therapies is a biotechnology company that develops gene therapies for serious genetic diseases that affect the central nervous system, especially rare disorders of the brain and spinal cord. Its work is centered on designing one-time treatments that try to address the root cause of disease by delivering a working copy of a gene into a patient’s cells. The company does not sell consumer products. It makes money mainly by advancing drug candidates through research and clinical development, and by using partnerships, licensing arrangements, and possible future commercialization of approved therapies. Its main customers, in the broad sense, are patients with rare inherited diseases and the doctors and hospitals that treat them, while larger pharmaceutical partners can also be part of the business model. What makes Taysha different is that it sits in the early stage of the gene-therapy value chain, where the goal is to create highly targeted treatments for very small patient groups that often have few or no good options. That means the company’s value depends on its scientific platform, its ability to run clinical studies, and whether regulators eventually approve its medicines.
